Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
| Treament |
Trials |
|
|
| clinical deterioration | clinical improvement | deaths | PCR-negative conversion |
| Immunostimulants drugs | 34 | 0.52 [0.28; 0.95], 3 RCTs, I2=6% demonstrated
low degree of certainty | 1.06 [0.78; 1.45], 5 RCTs, I2=45%
inconclusive result | 1.06 [0.98; 1.14], 15 RCTs, I2=0%
inconclusive result | 6.33 [1.54; 26.00], 1 RCT, I2=0%
unassessable degree of certainty | |
| Immunosuppressants drugs | 27 | 0.78 [0.53; 1.14], 4 RCTs, I2=36%
inconclusive result | 1.28 [1.10; 1.49], 9 RCTs, I2=42% demonstrated
low degree of certainty | 0.81 [0.66; 0.98], 10 RCTs, I2=0%
low degree of certainty | - | |
| corticosteroids | 15 | 0.81 [0.46; 1.42], 3 RCTs, I2=81%
inconclusive result | 1.16 [0.84; 1.60], 2 RCTs, I2=0%
inconclusive result | 0.87 [0.72; 1.05], 7 RCTs, I2=59% demonstrated
inconclusive result | - | |
| anti-inflammatory therapies | 8 | OBS 0.43 [0.02; 8.34], 2 studies, I2=88%
inconclusive result | OBS 12.75 [1.61; 100.79], 1 study, I2=0%
unassessable degree of certainty | OBS 0.85 [0.65; 1.10], 6 studies, I2=19%
inconclusive result | - | |
| acalabrutinib | 2 | - | - | - | - | |
| A EFFACER anticorps | 0 | - | - | - | - | |
| Apilimod | 0 | - | - | - | - | |
| imatinib | 0 | - | - | - | - | |
| leflunomide | 0 | - | - | - | - | |
| pirfenidone | 0 | - | - | - | - | |
| Polyinosinic-Polycytidylic Acid | 0 | - | - | - | - | |
| sargramostim | 0 | - | - | - | - | |
| thymosin | 0 | - | - | - | - | |
